Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI

NeuroImage

Volumn 72, Issue , 2013, Pages 1-9

  Schouw, M L J ^a,b   Kaag, A M ^a,b   Caan, M W A ^a,b   Heijtel, D F R ^a,b   Majoie, C B L M ^a,b   Nederveen, A J ^a,b   Booij, J ^a,b   Reneman, L ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ASL; CBF; Dextroamphetamine; Dopamine; PhMRI; SPECT

Indexed keywords

DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; IODINE 123;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN RADIOGRAPHY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; EUPHORIA; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMPULSIVENESS; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; POSTERIOR CINGULATE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING; VOXEL BASED MORPHOMETRY;

BRAIN; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBROVASCULAR CIRCULATION; DEXTROAMPHETAMINE; DOPAMINE; HEMODYNAMICS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPIN LABELS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84873742013     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.12.056     Document Type: Article

References (48)

1. Abi-Dargham A., Kegeles L.S., Martinez D., Innis R.B., Laruelle M. Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. Eur. Neuropsychopharmacol. 2003, 13:459-468.
2. Alttoa A., Seeman P., Koiv K., Eller M., Harro J. Rats with persistently high exploratory activity have both higher extracellular dopamine levels and higher proportion of D(2) (high) receptors in the striatum. Synapse 2009, 63:443-446.
3. Beckmann C.F., DeLuca M., Devlin J.T., Smith S.M. Investigations into resting-state connectivity using independent component analysis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360:1001-1013.
4. Bloom A.S., Hoffmann R.G., Fuller S.A., Pankiewicz J., Harsch H.H., Stein E.A. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum. Brain Mapp. 1999, 8:235-244.
5. Boileau I., Dagher A., Leyton M., Gunn R.N., Baker G.B., Diksic M., Benkelfat C. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch. Gen. Psychiatry 2006, 63:1386-1395.
6. Booij J., Korn P., Linszen D.H., Van Royen E.A. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur. J. Nucl. Med. 1997, 24:674-677.
7. Booij J., Busemann S.E., Stabin M.G., Janssen A.G., de Bruin K., van Royen E.A. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur. J. Nucl. Med. 1998, 25:24-30.
8. Bruns A., Kunnecke B., Risterucci C., Moreau J.L., von K.M. Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn. Reson. Med. 2009, 61:1451-1458.
9. Carver C.S., White T.L. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales. J Pers Soc Psychol 1994, 67:319-333.
10. Chalela J.A., Alsop D.C., Gonzalez-Atavales J.B., Maldjian J.A., Kasner S.E., Detre J.A. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000, 31:680-687.
11. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38:389-398.
12. Chen Y.I., Choi J.K., Jenkins B.G. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse 2005, 55:80-88.
13. Chen Y.I., Choi J.K., Xu H., Ren J., Andersen S.L., Jenkins B.G. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function. Dev. Neurosci. 2010, 32:125-138.
14. Choi J.K., Chen Y.I., Hamel E., Jenkins B.G. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 2006, 30:700-712.
15. Dai W., Garcia D., de B.C., Alsop D.C. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn. Reson. Med. 2008, 60:1488-1497.
16. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., Pena Y., Murphy E.R., Shah Y., Probst K., Abakumova I., Aigbirhio F.I., Richards H.K., Hong Y., Baron J.C., Everitt B.J., Robbins T.W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315:1267-1270.
17. Devous M.D., Trivedi M.H., Rush A.J. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J. Nucl. Med. 2001, 42:535-542.
18. Dixon A.L., Prior M., Morris P.M., Shah Y.B., Joseph M.H., Young A.M. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 2005, 48:236-245.
19. Gevers S., van Osch M.J., Bokkers R.P., Kies D.A., Teeuwisse W.M., Majoie C.B., Hendrikse J., Nederveen A.J. Intra- and multicenter reproducibility of pulsed, continuous and pseudo-continuous arterial spin labeling methods for measuring cerebral perfusion. J. Cereb. Blood Flow Metab. 2011, 31:1706-1715.
20. Golay X., Hendrikse J., Lim T.C. Perfusion imaging using arterial spin labeling. Top. Magn. Reson. Imaging 2004, 15:10-27.
21. Honey G., Bullmore E. Human pharmacological MRI. Trends Pharmacol. Sci. 2004, 25:366-374.
22. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 2004, 24:9553-9560.
23. Jenkinson M., Bannister P., Brady M., Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002, 17:825-841.
24. Kim N., Goel P.K., Tivarus M.E., Hillier A., Beversdorf D.Q. Independent component analysis of the effect of l-dopa on fMRI of language processing. PLoS One 2010, 5:e11933.
25. Kuczenski R., Segal D.S., Cho A.K., Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 1995, 15:1308-1317.
26. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Charney D.S., Hoffer P.B., Kung H.F. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 1995, 36:1182-1190.
27. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., Innis R.B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997, 17:162-174.
28. Lidow M.S., Goldman-Rakic P.S., Gallager D.W., Rakic P. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991, 40:657-671.
29. Luo F., Schmidt K.F., Fox G.B., Ferris C.F. Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment. J. Psychiatr. Res. 2009, 43:1018-1024.
30. Marota J.J., Mandeville J.B., Weisskoff R.M., Moskowitz M.A., Rosen B.R., Kosofsky B.E. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. Neuroimage 2000, 11:13-23.
31. McKittrick C.R., Abercrombie E.D. Catecholamine mapping within nucleus accumbens: differences in basal and amphetamine-stimulated efflux of norepinephrine and dopamine in shell and core. J. Neurochem. 2007, 100:1247-1256.
32. Melega W.P., Quintana J., Raleigh M.J., Stout D.B., Yu D.C., Lin K.P., Huang S.C., Phelps M.E. 6-[18F]fluoro-l-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse 1996, 22:63-69.
33. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
34. Nguyen T.V., Brownell A.L., Iris Chen Y.C., Livni E., Coyle J.T., Rosen B.R., Cavagna F., Jenkins B.G. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000, 36:57-65.
35. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67:53-83.
36. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 1995, 51:768-774.
37. Ren J., Xu H., Choi J.K., Jenkins B.G., Chen Y.I. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009, 63:764-772.
38. Rose S.E., Janke A.L., Strudwick M.W., McMahon K.L., Chalk J.B., Snyder P., De zubicaray G.I. Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: a human pharmacological magnetic resonance imaging study at 1.5 and 4T. Magn. Reson. Med. 2006, 55:9-15.
39. Sambataro F., Blasi G., Fazio L., Caforio G., Taurisano P., Romano R., Di G.A., Gelao B., Lo B.L., Papazacharias A., Popolizio T., Nardini M., Bertolino A. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacology 2010, 35:904-912.
40. Schwarz A.J., Zocchi A., Reese T., Gozzi A., Garzotti M., Varnier G., Curcuruto O., Sartori I., Girlanda E., Biscaro B., Crestan V., Bertani S., Heidbreder C., Bifone A. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. Neuroimage 2004, 23:296-304.
41. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155.
42. Tjandra T., Brooks J.C., Figueiredo P., Wise R., Matthews P.M., Tracey I. Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design. Neuroimage 2005, 27:393-401.
43. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J. Clin. Pharmacol. 2001, 21S-28S. (Suppl.).
44. van Kammen D., Murphy D. Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 1975, 44:215-224.
45. Ventura R., Cabib S., Alcaro A., Orsini C., Puglisi-Allegra S. Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J. Neurosci. 2003, 23:1879-1885.
46. Verhoeff N.P., Bobeldijk M., Feenstra M.G., Boer G.J., Maas M.A., Erdtsieck-Ernste E., de B.K., Van Royen E.A. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain. Int. J. Rad. Appl. Instrum. B 1991, 18:837-846.
47. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Angrist B., Hitzemann R., Lieberman J., Pappas N. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am. J. Psychiatry 1997, 154:50-55.
48. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Gifford A., Hitzemann R., Ding Y.S., Pappas N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am. J. Psychiatry 1999, 156:1440-1443.